Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.54
MDT's Cash to Debt is ranked lower than
72% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. MDT: 0.54 )
Ranked among companies with meaningful Cash to Debt only.
MDT' s 10-Year Cash to Debt Range
Min: 0.21  Med: 0.85 Max: 7.76
Current: 0.54
0.21
7.76
Equity to Asset 0.50
MDT's Equity to Asset is ranked lower than
69% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. MDT: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
MDT' s 10-Year Equity to Asset Range
Min: 0.48  Med: 0.58 Max: 0.79
Current: 0.5
0.48
0.79
Interest Coverage 5.65
MDT's Interest Coverage is ranked lower than
88% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. MDT: 5.65 )
Ranked among companies with meaningful Interest Coverage only.
MDT' s 10-Year Interest Coverage Range
Min: 5.65  Med: 22.05 Max: 352.69
Current: 5.65
5.65
352.69
F-Score: 4
Z-Score: 2.47
M-Score: -1.90
WACC vs ROIC
11.17%
9.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 18.59
MDT's Operating margin (%) is ranked higher than
88% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. MDT: 18.59 )
Ranked among companies with meaningful Operating margin (%) only.
MDT' s 10-Year Operating margin (%) Range
Min: 16.71  Med: 28.83 Max: 66.79
Current: 18.59
16.71
66.79
Net-margin (%) 13.20
MDT's Net-margin (%) is ranked higher than
85% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.45 vs. MDT: 13.20 )
Ranked among companies with meaningful Net-margin (%) only.
MDT' s 10-Year Net-margin (%) Range
Min: 11.03  Med: 19.66 Max: 22.78
Current: 13.2
11.03
22.78
ROE (%) 10.17
MDT's ROE (%) is ranked higher than
71% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. MDT: 10.17 )
Ranked among companies with meaningful ROE (%) only.
MDT' s 10-Year ROE (%) Range
Min: 7.36  Med: 20.87 Max: 32.99
Current: 10.17
7.36
32.99
ROA (%) 4.84
MDT's ROA (%) is ranked higher than
66% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: -0.62 vs. MDT: 4.84 )
Ranked among companies with meaningful ROA (%) only.
MDT' s 10-Year ROA (%) Range
Min: 3.7  Med: 11.74 Max: 23.74
Current: 4.84
3.7
23.74
ROC (Joel Greenblatt) (%) 62.17
MDT's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. MDT: 62.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 51.21  Med: 70.49 Max: 161.75
Current: 62.17
51.21
161.75
Revenue Growth (3Y)(%) 6.20
MDT's Revenue Growth (3Y)(%) is ranked higher than
60% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. MDT: 6.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 4.2  Med: 12.80 Max: 17.9
Current: 6.2
4.2
17.9
EBITDA Growth (3Y)(%) 0.50
MDT's EBITDA Growth (3Y)(%) is ranked lower than
53% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. MDT: 0.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MDT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -15.5  Med: 9.90 Max: 45.4
Current: 0.5
-15.5
45.4
EPS Growth (3Y)(%) -9.20
MDT's EPS Growth (3Y)(%) is ranked lower than
59% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: -2.00 vs. MDT: -9.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MDT' s 10-Year EPS Growth (3Y)(%) Range
Min: -9.2  Med: 13.50 Max: 27.1
Current: -9.2
-9.2
27.1
» MDT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MDT Guru Trades in Q2 2014

Robert Olstein 115,000 sh (New)
First Eagle Investment 2,098,343 sh (New)
Mario Gabelli 40,000 sh (New)
Jim Simons 2,312,700 sh (+53.45%)
Pioneer Investments 1,113,090 sh (+37.53%)
Vanguard Health Care Fund 12,402,000 sh (+9.39%)
James Barrow 32,340,234 sh (+1.96%)
John Buckingham 19,010 sh (+0.97%)
Bill Frels 4,146,152 sh (+0.53%)
Bill Nygren 4,605,000 sh (+0.44%)
Steven Cohen 933,000 sh (unchged)
Steven Cohen 250,000 sh (unchged)
Ray Dalio Sold Out
John Hussman Sold Out
Manning & Napier Advisors, Inc Sold Out
Scott Black 42,983 sh (-0.16%)
Jeff Auxier 149,320 sh (-0.93%)
John Keeley 33,460 sh (-2.05%)
Dodge & Cox 8,776,593 sh (-2.29%)
Paul Tudor Jones 10,500 sh (-5.41%)
PRIMECAP Management 29,602,228 sh (-6.23%)
HOTCHKIS & WILEY 1,932,500 sh (-6.50%)
Ken Fisher 6,015 sh (-12.23%)
Diamond Hill Capital 4,605,630 sh (-13.90%)
Jeremy Grantham 5,518,126 sh (-21.73%)
Chuck Royce 66,100 sh (-48.68%)
Joel Greenblatt 9,398 sh (-96.16%)
» More
Q3 2014

MDT Guru Trades in Q3 2014

Andreas Halvorsen 1,841,414 sh (New)
Ruane Cunniff 9,700 sh (New)
Ray Dalio 27,045 sh (New)
Joel Greenblatt 496,211 sh (+5179.96%)
HOTCHKIS & WILEY 3,230,958 sh (+67.19%)
Robert Olstein 142,000 sh (+23.48%)
Paul Tudor Jones 11,500 sh (+9.52%)
Ken Fisher 6,165 sh (+2.49%)
Bill Nygren 4,690,000 sh (+1.85%)
Dodge & Cox 8,864,623 sh (+1.00%)
John Buckingham 19,152 sh (+0.75%)
James Barrow 32,479,848 sh (+0.43%)
Pioneer Investments 976,081 sh (unchged)
Vanguard Health Care Fund 12,402,000 sh (unchged)
John Keeley 33,460 sh (unchged)
Mario Gabelli 40,000 sh (unchged)
Scott Black Sold Out
Chuck Royce Sold Out
PRIMECAP Management 29,535,573 sh (-0.23%)
Jeff Auxier 146,345 sh (-1.99%)
Jim Simons 2,200,400 sh (-4.86%)
Bill Frels 3,768,038 sh (-9.12%)
First Eagle Investment 1,790,484 sh (-14.67%)
Diamond Hill Capital 3,703,791 sh (-19.58%)
Steven Cohen 265,300 sh (-71.56%)
Jeremy Grantham 551,007 sh (-90.01%)
» More
Q4 2014

MDT Guru Trades in Q4 2014

John Hussman 200,000 sh (New)
Steven Cohen 658,900 sh (+148.36%)
Ray Dalio 36,632 sh (+35.45%)
Vanguard Health Care Fund 13,047,000 sh (+5.20%)
James Barrow 32,638,454 sh (+0.49%)
Ken Fisher 6,193 sh (+0.45%)
Bill Nygren 4,690,000 sh (unchged)
Andreas Halvorsen Sold Out
Jim Simons Sold Out
Jeff Auxier 145,895 sh (-0.31%)
Dodge & Cox 8,817,773 sh (-0.53%)
John Buckingham 19,051 sh (-0.53%)
Diamond Hill Capital 3,678,388 sh (-0.69%)
HOTCHKIS & WILEY 3,207,884 sh (-0.71%)
John Keeley 33,180 sh (-0.84%)
Robert Olstein 134,000 sh (-5.63%)
Bill Frels 3,396,496 sh (-9.86%)
Pioneer Investments 788,292 sh (-19.24%)
First Eagle Investment 1,236,314 sh (-30.95%)
PRIMECAP Management 18,578,166 sh (-37.10%)
Ruane Cunniff 4,700 sh (-51.55%)
Paul Tudor Jones 3,800 sh (-66.96%)
Mario Gabelli 10,000 sh (-75.00%)
Joel Greenblatt 19,608 sh (-96.05%)
Jeremy Grantham 4,046 sh (-99.27%)
Steven Romick -2,425,900 sh (-9999.00%)
» More
Q1 2015

MDT Guru Trades in Q1 2015

First Pacific Advisors 2,147,307 sh (New)
Caxton Associates 30,000 sh (New)
Ronald Muhlenkamp 173,653 sh (New)
Louis Moore Bacon 25,233 sh (New)
Jeremy Grantham 7,402,676 sh (+182862.83%)
Mario Gabelli 66,282 sh (+562.82%)
Ray Dalio 172,832 sh (+371.81%)
Pioneer Investments 2,760,285 sh (+250.16%)
Paul Tudor Jones 11,800 sh (+210.53%)
Joel Greenblatt 37,793 sh (+92.74%)
HOTCHKIS & WILEY 5,753,016 sh (+79.34%)
Vanguard Health Care Fund 18,885,933 sh (+44.75%)
John Keeley 40,512 sh (+22.10%)
Ken Fisher 6,717 sh (+8.46%)
Ruane Cunniff 4,880 sh (+3.83%)
John Buckingham 19,377 sh (+1.71%)
John Hussman 200,000 sh (unchged)
Bill Nygren 4,690,000 sh (unchged)
Robert Olstein 134,000 sh (unchged)
Dodge & Cox 8,696,577 sh (-1.37%)
James Barrow 31,889,163 sh (-2.30%)
Diamond Hill Capital 3,566,702 sh (-3.04%)
Bill Frels 3,254,448 sh (-4.18%)
PRIMECAP Management 17,545,221 sh (-5.56%)
First Eagle Investment 937,172 sh (-24.20%)
Jeff Auxier 45,530 sh (-68.79%)
Steven Cohen 136,200 sh (-79.33%)
Steven Romick 2,020,579 sh (-183.29%)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Medtronic PLC

Bill Frels Comments on Medtronic Inc - Oct 20, 2014

Healthcare company Medtronic, Inc. (MDT) detracted slightly from performance during the period. Pending a shareholder vote later this year or in 2015, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Your Growth Fund portfolio managers are pleased to report that we have completed our valuation for Medtronic. As of October 7, 2014 we believe combined Medtronic/Covidien to be $8 per share more valuable than shares of Medtronic alone.

As of September 30, 2014, the market value of the Growth Fund’s holding in Medtronic was $24 per share greater than its cost basis. We estimate that our typical shareholder, that holds the Growth Fund in a taxable amount, will experience about a $6.00 per share tax liability. We do not offer tax advice; each shareholder should consult a tax advisor about his/her particular circumstance. Providing that there are no significant changes, our current thinking leads us to believe that voting for the merger is in our shareholders’ best interest. We will keep you posted as the voting date is finalized or if we learn of any other developments regarding the merger plans.

From Bill Frels (Trades, Portfolio)' Mairs & Power Growth Fund Q3 2014 Commentary.

Check out Bill Frels latest stock trades

Bill Frels Comments on Medtronic Inc - Jul 31, 2014

Healthcare company Medtronic, Inc. (MDT) also contributed to performance, gaining 3.61% and 11.10% for the second quarter and first six months, respectively. Pending a shareholder vote later this year or in 2015, however, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Once completed, the merger will create a taxable event for Fund shareholders who will realize a long-term capital gain estimated at $60 million or $1.50 a share.

From Bill Frels (Trades, Portfolio)’ Mairs & Power Growth Fund Second Quarter 2014 Commentary.

Check out Bill Frels latest stock trades

Bill Frels Comments on Medtronic Inc - Jun 25, 2014

Healthcare company Medtronic, Inc. (MDT) also finished the quarter as a top five contributor to the Fund, gaining 7.23%. While emerging market revenue proved scarce for most industries during the quarter, Medtronic increased its share of revenue from the developing world by 15%, which represented 12% of the company’s revenue.



From Bill Frels' Mairs & Power Balance Fund First Quarter 2014 Commentary.



Check out Bill Frels latest stock trades

Top Ranked Articles about Medtronic PLC

Hotchkis & Wiley Add to Banking, Insurance Stakes
In its 35-year existence, value investor HOTCHKIS & WILEY has built its reputation on identifying undervalued companies that have great growth potential. But in the first quarter, most of its emphasis was on well-established companies, especially those in banking and insurance. Read more...
Steven Romick Shorts Alibaba, Medtronic in Q4
Steven Romick (Trades, Portfolio) is the portfolio manager of the long-short FPA Crescent Fund. During the fourth quarter, Romick shorted four additional positions, bringing the fund’s total number of short positions to 29. Read more...
Bill Frels Comments on Medtronic Inc
Healthcare company Medtronic, Inc. (MDT) detracted slightly from performance during the period. Pending a shareholder vote later this year or in 2015, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Your Growth Fund portfolio managers are pleased to report that we have completed our valuation for Medtronic. As of October 7, 2014 we believe combined Medtronic/Covidien to be $8 per share more valuable than shares of Medtronic alone. Read more...
Bill Frels Comments on Medtronic Inc
Healthcare company Medtronic, Inc. (MDT) also contributed to performance, gaining 3.61% and 11.10% for the second quarter and first six months, respectively. Pending a shareholder vote later this year or in 2015, however, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Once completed, the merger will create a taxable event for Fund shareholders who will realize a long-term capital gain estimated at $60 million or $1.50 a share. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.81
MDT's P/E(ttm) is ranked higher than
51% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 28.20 vs. MDT: 27.81 )
Ranked among companies with meaningful P/E(ttm) only.
MDT' s 10-Year P/E(ttm) Range
Min: 10.14  Med: 20.67 Max: 43.51
Current: 27.81
10.14
43.51
Forward P/E 16.69
MDT's Forward P/E is ranked higher than
73% of the 97 Companies
in the Global Medical Devices industry.

( Industry Median: 22.68 vs. MDT: 16.69 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.10
MDT's PE(NRI) is ranked higher than
51% of the 153 Companies
in the Global Medical Devices industry.

( Industry Median: 28.20 vs. MDT: 28.10 )
Ranked among companies with meaningful PE(NRI) only.
MDT' s 10-Year PE(NRI) Range
Min: 10.13  Med: 20.69 Max: 43.51
Current: 28.1
10.13
43.51
P/B 1.99
MDT's P/B is ranked higher than
71% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. MDT: 1.99 )
Ranked among companies with meaningful P/B only.
MDT' s 10-Year P/B Range
Min: 1.96  Med: 3.27 Max: 6.59
Current: 1.99
1.96
6.59
P/S 4.07
MDT's P/S is ranked lower than
60% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. MDT: 4.07 )
Ranked among companies with meaningful P/S only.
MDT' s 10-Year P/S Range
Min: 1.92  Med: 3.58 Max: 6.78
Current: 4.07
1.92
6.78
PFCF 19.37
MDT's PFCF is ranked higher than
74% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 32.21 vs. MDT: 19.37 )
Ranked among companies with meaningful PFCF only.
MDT' s 10-Year PFCF Range
Min: 9.2  Med: 15.26 Max: 70.14
Current: 19.37
9.2
70.14
POCF 17.18
MDT's POCF is ranked higher than
65% of the 148 Companies
in the Global Medical Devices industry.

( Industry Median: 21.95 vs. MDT: 17.18 )
Ranked among companies with meaningful POCF only.
MDT' s 10-Year POCF Range
Min: 8.13  Med: 12.99 Max: 32.39
Current: 17.18
8.13
32.39
EV-to-EBIT 12.45
MDT's EV-to-EBIT is ranked higher than
79% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 22.01 vs. MDT: 12.45 )
Ranked among companies with meaningful EV-to-EBIT only.
MDT' s 10-Year EV-to-EBIT Range
Min: 8.8  Med: 16.70 Max: 34.2
Current: 12.45
8.8
34.2
PEG 14.05
MDT's PEG is ranked lower than
91% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. MDT: 14.05 )
Ranked among companies with meaningful PEG only.
MDT' s 10-Year PEG Range
Min: 1.06  Med: 1.88 Max: 14.47
Current: 14.05
1.06
14.47
Shiller P/E 23.65
MDT's Shiller P/E is ranked higher than
68% of the 95 Companies
in the Global Medical Devices industry.

( Industry Median: 31.07 vs. MDT: 23.65 )
Ranked among companies with meaningful Shiller P/E only.
MDT' s 10-Year Shiller P/E Range
Min: 12.16  Med: 20.43 Max: 47.54
Current: 23.65
12.16
47.54
Current Ratio 3.36
MDT's Current Ratio is ranked higher than
59% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. MDT: 3.36 )
Ranked among companies with meaningful Current Ratio only.
MDT' s 10-Year Current Ratio Range
Min: 0.88  Med: 2.45 Max: 4.52
Current: 3.36
0.88
4.52
Quick Ratio 2.98
MDT's Quick Ratio is ranked higher than
64% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. MDT: 2.98 )
Ranked among companies with meaningful Quick Ratio only.
MDT' s 10-Year Quick Ratio Range
Min: 0.69  Med: 2.02 Max: 4.09
Current: 2.98
0.69
4.09
Days Inventory 124.64
MDT's Days Inventory is ranked higher than
53% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 129.39 vs. MDT: 124.64 )
Ranked among companies with meaningful Days Inventory only.
MDT' s 10-Year Days Inventory Range
Min: 132.14  Med: 155.34 Max: 232.97
Current: 124.64
132.14
232.97
Days Sales Outstanding 92.09
MDT's Days Sales Outstanding is ranked lower than
67% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 68.45 vs. MDT: 92.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDT' s 10-Year Days Sales Outstanding Range
Min: 64.09  Med: 82.62 Max: 92.09
Current: 92.09
64.09
92.09

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.74
MDT's Dividend Yield is ranked higher than
63% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. MDT: 1.74 )
Ranked among companies with meaningful Dividend Yield only.
MDT' s 10-Year Dividend Yield Range
Min: 0.59  Med: 1.81 Max: 2.93
Current: 1.74
0.59
2.93
Dividend Payout 0.51
MDT's Dividend Payout is ranked higher than
73% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 0.41 vs. MDT: 0.51 )
Ranked among companies with meaningful Dividend Payout only.
MDT' s 10-Year Dividend Payout Range
Min: 0.14  Med: 0.25 Max: 0.51
Current: 0.51
0.14
0.51
Dividend growth (3y) 7.90
MDT's Dividend growth (3y) is ranked higher than
60% of the 48 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. MDT: 7.90 )
Ranked among companies with meaningful Dividend growth (3y) only.
MDT' s 10-Year Dividend growth (3y) Range
Min: 7.6  Med: 15.50 Max: 26
Current: 7.9
7.6
26
Yield on cost (5-Year) 2.61
MDT's Yield on cost (5-Year) is ranked higher than
73% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 1.37 vs. MDT: 2.61 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MDT' s 10-Year Yield on cost (5-Year) Range
Min: 0.87  Med: 2.67 Max: 4.33
Current: 2.61
0.87
4.33
Share Buyback Rate -1.50
MDT's Share Buyback Rate is ranked higher than
60% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. MDT: -1.50 )
Ranked among companies with meaningful Share Buyback Rate only.
MDT' s 10-Year Share Buyback Rate Range
Min: 2.6  Med: 0.30 Max: -8.3
Current: -1.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.29
MDT's Price/Projected FCF is ranked higher than
76% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. MDT: 1.29 )
Ranked among companies with meaningful Price/Projected FCF only.
MDT' s 10-Year Price/Projected FCF Range
Min: 0.77  Med: 1.55 Max: 6.95
Current: 1.29
0.77
6.95
Price/DCF (Earnings Based) 2.48
MDT's Price/DCF (Earnings Based) is ranked lower than
81% of the 16 Companies
in the Global Medical Devices industry.

( Industry Median: 1.68 vs. MDT: 2.48 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.14
MDT's Price/Median PS Value is ranked higher than
50% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.16 vs. MDT: 1.14 )
Ranked among companies with meaningful Price/Median PS Value only.
MDT' s 10-Year Price/Median PS Value Range
Min: 0.69  Med: 1.56 Max: 3.54
Current: 1.14
0.69
3.54
Earnings Yield (Greenblatt) (%) 8.08
MDT's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. MDT: 8.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2.9  Med: 6.00 Max: 11.3
Current: 8.08
2.9
11.3
Forward Rate of Return (Yacktman) (%) 7.19
MDT's Forward Rate of Return (Yacktman) (%) is ranked higher than
61% of the 98 Companies
in the Global Medical Devices industry.

( Industry Median: 4.08 vs. MDT: 7.19 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MDT' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 7  Med: 15.15 Max: 23.8
Current: 7.19
7
23.8

Analyst Estimate

Apr16 Apr17
Revenue(Mil) 28,843 29,975
EPS($) 4.39 4.86
EPS without NRI($) 4.39 4.86

Business Description

Industry: Medical Devices » Medical Devices
Compare:SYK, SMA, ZMH, STJ, EW » details
Traded in other countries:2M6.Germany, MDT.Argentina, 0QYG.UK, MDT.Switzerland, MDT N.Mexico,
Medtronic PLC was founded in 1949, incorporated as a Minnesota corporation in 1957. The Company is a medical technology company - alleviating pain, restoring health, and extending life for millions of people around the world. The Company develops, manufactures, and markets its medical devices in more than 140 countries. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, and ear, nose, and throat and diabetes conditions. The Company functions in three operating segments that manufacture and sell device-based medical therapies: Cardiac and Vascular Group; Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group includes Cardiac Rhythm Disease Management that develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, information systems for the management of patients with CRDM devices, and an integrated health solutions business; Coronary which includes therapies to treat coronary artery disease (CAD) and hypertension. The products contained within this business include coronary stents and related delivery systems, including a broad line of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters, and accessories; The Structural Heart business offers a comprehensive line of products and therapies to treat a variety of heart valve disorders. Its products include products for the repair and replacement of heart valves, perfusion systems, positioning and stabilization systems for beating heart revascularization surgery, and surgical ablation products; The Endovascular business is comprised of a comprehensive line of products and therapies to treat aortic disease (such as aneurysms, dissections, and transections) as well as peripheral vascular disease (PVD). Its products include endovascular stent graft systems, peripheral stent and angioplasty systems, and carotid embolic protection systems for the treatment of vascular disease outside the heart. The Restorative Therapies Group includes Spine business which develops, manufactures, and markets a comprehensive line of medical devices and implants used in the treatment of the spine and musculoskeletal system. Its products and therapies treat a variety of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumors, fractures of the spine, and stenosis. Its Spine business also provides biologic solutions for the orthopedic and dental markets. Its Neuromodulation business includes implantable neurostimulation and targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity, and uro
» More Articles for MDT

Headlines

Articles On GuruFocus.com
Hotchkis & Wiley Add to Banking, Insurance Stakes Jun 26 2015 
Looking Ahead of Wall Street: Ambarella Inc., Dollar General Corp., Medtronic PLC Jun 01 2015 
First Pacific Advisors Purchase New Positions During 1QFY15 May 22 2015 
My Stock Watch List For April 2015 Apr 05 2015 
Mairs & Power Balanced Fund Q4 2014 Commentary Mar 31 2015 
Freedom Fund Update – March 2015 Mar 02 2015 
Medtronic (MDT) Momentum at All-Time-High Levels, Knowles (KN) Rating Boosted Feb 21 2015 
Medtronic Q3 Earnings 2015 Exceeds Market Expectations Feb 19 2015 
A Robust Q4 Earnings Report From Boston Scientific Feb 10 2015 
A Look at John Hussman's Recent Additions to His Portfolio Feb 06 2015 

More From Other Websites
Integra to Acquire TEI, Expand in Regenerative Wound Care - Analyst Blog Jun 30 2015
American Heart Association's New Stroke Treatment Guidelines Establish Stent Retrievers as... Jun 29 2015
American Heart Association's New Stroke Treatment Guidelines Establish Stent Retrievers as... Jun 29 2015
A first: New guidelines back device for treating strokes Jun 29 2015
A first: New guidelines back device for treating strokes Jun 29 2015
Hotchkis & Wiley Add to Banking, Insurance Stakes Jun 26 2015
Medtronic Recalls Faulty Tracheostomy Tubes, Stock Down - Analyst Blog Jun 26 2015
Medtronic's CoreValve Evolut R TAVR System Wins FDA Nod - Analyst Blog Jun 25 2015
Medtronic Announces Expansion of MR-Conditional Products with U.S. Launch of Advisa SR MRI(TM)... Jun 25 2015
Medtronic Announces Expansion of MR-Conditional Products with U.S. Launch of Advisa SR MRI(TM)... Jun 25 2015
Medtronic Names Geoff Martha Executive Vice President and President, Restorative Therapies Group Jun 25 2015
Medtronic Names Geoff Martha Executive Vice President and President, Restorative Therapies Group Jun 25 2015
America's top states for innovation in 2015 Jun 24 2015
Covidien agrees to settle some cases over transvaginal mesh devices Jun 24 2015
World's Smallest Pacemaker, Medtronic Micra TPS, Wins Top European Innovation Award for 2015 Jun 24 2015
World's Smallest Pacemaker, Medtronic Micra TPS, Wins Top European Innovation Award for 2015 Jun 24 2015
Medtronic recalls breathing devices after serious injury reports Jun 23 2015
Medtronic Implements Worldwide Voluntary Recall for Certain Lots of Neonatal and Pediatric... Jun 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK